Morgan Stanley initiated coverage on Silence Therapeutics with a new price target
$SLN
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley initiated coverage of Silence Therapeutics with a rating of Overweight and set a new price target of $20.00